Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
TLDR
In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin.Abstract:
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin. Methods—A Markov decision-analysis model was constructed using data from clinical trials to evaluate lifetime costs and quality-adjusted life-years of novel oral anticoagulants compared with warfarin. The modeled population was a hypothetical cohort of 70-year-old patients with nonvalvular atrial fibrillation, increased risk for stroke (CHADS2 ≥1), renal creatinine clearance ≥50 mL/min, and no previous contraindications to anticoagulation. The willingness-to-pay threshold was $50 000/quality-adjusted life-years gained. Results—In the base case, warfarin had the lowest cost of $77 813 (SD, $2223), followed by rivaroxaban 20 mg ($78 738±$1852), dabigatran 150 mg ($82 719±$1959), and apixaban 5 mg ($85 326±$1512). Apixaban 5 mg had the highest quality-adjusted life-year...read more
Citations
More filters
Journal ArticleDOI
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.
François Laliberté,Veronica Ashton,Akshay Kharat,Dominique Lejeune,Kenneth Todd Moore,Young Jung,Patrick Lefebvre,Jeffrey S. Berger +7 more
TL;DR: In this article, the authors evaluated healthcare resource utilization (HRU) and costs associated with rivaroxaban and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and polypharmacy.
Book ChapterDOI
13. Acute cardiac disease in elder patients
Susanne DeMeester,Amal Mattu,Shamai A. Grossman,Shamai A. Grossman,Peter L. Rosen,Peter L. Rosen +5 more
Journal ArticleDOI
Nouveaux anticoagulants oraux
TL;DR: Les nouveaux anticoagulants oraux inhibent directement des facteurs de the coagulation : facteur IIa pour le dabigatran, facteur–Xa for le rivaroxaban and l’apixaban, yn â’in conclusion que leur utilisation apparait simple car leur posologie est fixe.
Journal ArticleDOI
Cost‐effectiveness of rivaroxaban versus warfarin in non‐valvular atrial fibrillation patients with chronic kidney disease in China
TL;DR: This study aimed to estimate the cost‐effectiveness of rivaroxaban compared with warfarin in Chinese NVAF patients with CKD.
Journal ArticleDOI
Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension
Chia Te Liao,Han Siong Toh,Li Sun,Chun Ting Yang,Angie Hu,Dong-Mei Wei,Jesus D. Melgarejo,Zhenyu Zhang +7 more
TL;DR: In this paper , an economic evaluation with a Markov model and extensive sensitivity analyses estimated the incremental lifetime medical costs, quality-adjusted life-years (QALYs), and costeffectiveness of intensive vs standard blood pressure targets for older patients with hypertension in China, the US, and the UK.
References
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel,Kenneth W. Mahaffey,Jyotsna Garg,Guohua Pan,Daniel E. Singer,Werner Hacke,Günter Breithardt,Jonathan L. Halperin,Graeme J. Hankey,Jonathan P. Piccini,Richard C. Becker,Christopher C. Nessel,John F. Paolini,Scott D. Berkowitz,Robert M. Califf +14 more
TL;DR: In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
TL;DR: The data suggest that the elderly are particularly vulnerable to stroke when atrial fibrillation is present, and the effects of hypertension, coronary heart disease, and cardiac failure on the risk of stroke became progressively weaker with increasing age.
Journal ArticleDOI
Heart Disease and Stroke Statistics—2011 Update A Report From the American Heart Association
Véronique L. Roger,Alan S. Go,Donald M. Lloyd-Jones,Robert J. Adams,Jarett D. Berry,Todd M. Brown,Mercedes R. Carnethon,Shifan Dai,Giovanni de Simone,Earl S. Ford,Caroline S. Fox,Heather J. Fullerton,Cathleen Gillespie,Kurt J. Greenlund,Susan M. Hailpern,John A. Heit,P. Michael Ho,Virginia J. Howard,Brett M. Kissela,Steven J. Kittner,Daniel T. Lackland,Judith H. Lichtman,Lynda D. Lisabeth,Diane M. Makuc,Gregory M. Marcus,Ariane Marelli,David B. Matchar,Mary M. McDermott,James B. Meigs,Claudia S. Moy,Dariush Mozaffarian,Michael E. Mussolino,Graham Nichol,Nina P. Paynter,Wayne D. Rosamond,Paul D. Sorlie,Randall S. Stafford,Tanya N. Turan,Melanie B. Turner,Nathan D. Wong,Judith Wylie-Rosett +40 more
TL;DR: Dariush Mozaffarian, Michael E. Mussolino, Graham Nichol, Nina P. Paynter, Wayne D. Sorlie, Randall S. Stafford, Tanya N. Turan, Melanie B. Turner, Nathan D. Turner.
Related Papers (5)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Dabigatran versus warfarin in patients with atrial fibrillation
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
Edoxaban versus warfarin in patients with atrial fibrillation
Robert P. Giugliano,Christian T. Ruff,Eugene Braunwald,Sabina A. Murphy,Stephen D. Wiviott,Jonathan L. Halperin,Albert L. Waldo,Michael D. Ezekowitz,Jeffrey I. Weitz,Witold Rużyłło,Mikhail Ruda,Yukihiro Koretsune,Joshua Betcher,Minggao Shi,Laura T. Grip,Laura T. Grip,Shirali P. Patel,Indravadan Patel,James J. Hanyok,Michele Mercuri,Elliott M. Antman,Elliott M. Antman,Abstr Act,Abstr Act +23 more